About BridgeBio Oncology Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://bbotx.com/
Frequently Asked Questions
What is the 52-week range for BBOT?
The 52-week high is $14.87 and the 52-week low is $3.79.
What is the P/E ratio for BBOT?
The P/E ratio data is currently unavailable.
What is the dividend yield for BBOT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.90%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.44.
Analyst Recommendation Trends
Wall Street analyst consensus for BBOT over the last few months:
Latest BBOT News
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other […]
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON) shares
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (DCR) of 100% (41/41) and no grade 3 liver enzyme elevationsBBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC$344.1 million in cash, cash equivalents and marketable securi
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive ORR in the 2L+
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-10 | Cobo Marc | +43,700 | - | - |
| 2026-09-10 | Cobo Marc | -203 | $5.52 | $1,121 |
| 2026-09-10 | Cobo Marc | +9,038 | - | - |
| 2026-07-01 | Elmelech Idan | -343 | $7.8 | $2,675 |
| 2026-07-01 | Ben Yong | -1,047 | $7.8 | $8,167 |
| 2026-07-01 | Beltran Pedro | -1,047 | $7.8 | $8,167 |
| 2026-07-01 | Cobo Marc | -125 | $7.8 | $975 |
| 2026-07-01 | Chen Bihua | +130,865 | - | - |
| 2026-07-01 | Chen Bihua | +1,704,862 | - | - |
| 2026-07-01 | Chen Bihua | +2,692,459 | - | - |
| 2026-07-01 | Chen Bihua | -4,528,186 | - | - |
| 2026-06-16 | Bauer Jake | +31,675 | - | - |
| 2026-06-16 | Chen Bihua | +31,675 | - | - |
| 2026-06-16 | MCCORMICK FRANK | +31,675 | - | - |
| 2026-05-10 | Elmelech Idan | +758,222 | - | - |
| 2026-05-10 | Beltran Pedro | +1,103,837 | - | - |
| 2026-04-01 | Ben Yong | -1,047 | $9.03 | $9,454 |
| 2026-04-01 | Beltran Pedro | -1,047 | $9.03 | $9,454 |
| 2026-04-01 | Mehra Uneek | -524 | $9.03 | $4,732 |
| 2026-03-24 | Lebowitz Peter F | +63,350 | - | - |
| 2026-03-10 | Mehra Uneek | +105,000 | - | - |
| 2026-03-10 | Mehra Uneek | +23,330 | - | - |
| 2026-03-10 | Beltran Pedro | +210,000 | - | - |
| 2026-03-10 | Beltran Pedro | +46,670 | - | - |
| 2026-03-10 | Ben Yong | +210,000 | - | - |
| 2026-03-10 | Ben Yong | +46,670 | - | - |
| 2026-01-01 | Wallace Eli M. | +1,114,400 | - | - |
| 2025-12-10 | Wallace Eli M. | -1,114,400 | - | - |
| 2025-10-10 | BridgeBio Pharma, Inc. | +784,720 | - | - |